Singapore - GSK
Tuas is a key manufacturing site within our network supplying the active ingredient used to make our pneumococcal conjugate vaccine. This paediatric vaccine is indicated for the active immunisation against pneumonia caused by Streptococcus pneumoniae, invasive diseases and acute otitis media caused by Streptococcus pneumoniae in infants and ...
GSK today celebrated the groundbreaking of its S$343 million state-of-the-art vaccines facility at Tuas which will manufacture drug substances for GSK’s vaccines that protect against Hepatitis B. This
GlaxoSmithKline Vaccine Manufacturing Facility, Tuas
2007年11月19日 · The Tuas vaccine plant, which will be GSK's first vaccine facility in Asia, will focus on the production of two bulk paediatric vaccines for preventing infectious disease such as meningitis and typhoid. Later products may be vaccines against …
GSK invests S$343 million in state-of-the-art vaccines facility ...
2023年7月13日 · Global biopharmaceutical powerhouse GSK is expanding its Tuas vaccines facility in Singapore and will begin producing drug substances for Hepatitis B vaccines when commercial production commences in 2027.
GSK’s Tuas vaccine facility is Singapore’s largest after over $300m ...
2023年7月13日 · British drugmaker GSK's vaccine manufacturing facility in Tuas. PHOTO: LIANHE ZAOBAO. SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of...
GSK invests S$343 million in state-of-the-art vaccines facility ...
Our vaccines facility at Tuas is a key manufacturing site within our global network supplying the active ingredients used to make multiple paediatric vaccines. To date, the site has played a key role in producing more than 800 million vaccines for serious childhood invasive diseases which include pneumonia and meningitis.
GSK’s Tuas facility becomes SG’s largest vaccine production site …
2023年7月14日 · GSK’s facility in Tuas is now Singapore’s largest vaccine production site in terms of cumulative investment, according to Trade Minister Gan Kim Yong. Gan, in his speech at the groundbreaking of the facility’s expansion, said …
Speech by Minister Gan Kim Yong, Guest-of-Honour at GSK’s …
2023年7月13日 · As part of this investment, GSK will be transferring their next-generation process for their Hepatitis B vaccine (HBV) vaccine to the Tuas site. a. Hepatitis B is a dangerous disease, causing serious complications in the liver. It affects 1 in 25 people in Singapore today. b.
GSK’s Tuas vaccine facility is Singapore’s largest after S$300 …
2023年7月13日 · The expansion of British drugmaker GSK’s facility at Tuas has earned it the title of Singapore’s largest vaccine production site based on a cumulative investment of some S$850 million, said Minister for Trade and Industry Gan Kim Yong.
GSK today celebrated the groundbreaking of its S$343 million state-of-the-art vaccines facility at Tuas which will manufacture drug substances for GSK’s vaccines that protect against Hepatitis B. This expansion of the existing GSK facility at Tuas will start construction in the third quarter of 2023, with completion targeted by 2025.